Comparison of Myocardial Infarction Patients Who Were Prescribed a Novel Antiplatelet Agent or Clopidogrel
NCT ID: NCT05599152
Last Updated: 2022-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
3000 participants
OBSERVATIONAL
2020-05-21
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ticagrelor/prasugrel Group
Patients with acute myocardial infarction who underwent percutaneous coronary intervention and maintained aspirin and ticagrelor/prasugrel as standard therapy.
No interventions assigned to this group
clopidogrel Group
In patients with acute myocardial infarction who underwent percutaneous coronary intervention, discontinued ticagrelor/prasugrel and switched to clopidogrel
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who switched to clopidogrel after 30-90 days.
* Patients with a diagnosis code for Venus myocardial infarction and a prescription code for percutaneous cardiovascular intervention in the National Health Insurance data.
* Adults 18 years of age or older
Exclusion Criteria
* Those who have data for oral anticoagulants (warfarin, Coumadin, apixaban, edoxaban, dabigatran, rivaroxaban) in the National Health Insurance data
* Those who have a diagnosis code for malignant tumor in the National Health Insurance data
* Those who have end-stage renal failure code in the National Health Insurance data or those who have data for hemo/peritoneal dialysis
* A person who has a request for blood transfusion during the period of using Ticagrelor/prasugrel
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Chan Joon Kim
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chan Joon Kim
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chan Joon Kim
Role: PRINCIPAL_INVESTIGATOR
The Catholic University of Korea, Uijeongbu ST. Mary's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Catholic University of Korea, Uijeongbu ST. Mary's Hospital
Uijeongbu-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
UMT
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CKD-HIRA-Data-Review
Identifier Type: -
Identifier Source: org_study_id